title: The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.
abstract: Transient hepadnavirus infections can involve spread of virus to the entire hepatocyte population. In this situation hepatocytes present following recovery are derived from infected hepatocytes. During virus clearance antiviral cytokines are thought to block virus replication and formation of new covalently closed circular DNA (cccDNA), the viral transcriptional template. It remains unclear if existing cccDNA is eliminated noncytolytically or if hepatocyte death and proliferation, to compensate for killing of some of the infected hepatocytes, are needed to remove cccDNA from surviving infected hepatocytes. Interpreting the relationship between hepatocyte death and cccDNA elimination requires knowing both the amount of hepatocyte turnover and whether cccDNA synthesis is effectively blocked during the period of immune destruction of infected hepatocytes. We have addressed these questions by asking if treatment of woodchucks with the nucleoside analog inhibitor of viral DNA synthesis entecavir (ETV) reduced hepatocyte turnover during clearance of transient woodchuck hepatitis virus (WHV) infections. To estimate hepatocyte turnover, complexity analysis was carried out on virus-cell DNA junctions created by integration of WHV and present following recovery in the livers of WHV-infected control or ETV-treated woodchucks. We estimated that, on average, 2.2 to 4.8 times less hepatocyte turnover occurred during immune clearance in the ETV-treated woodchucks. Computer modeling of the complexity data suggests that mechanisms in addition to hepatocyte death were responsible for elimination of cccDNA during recovery from transient infections.
authors.affiliation: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. ws_mason@fccc.edu
authors.forename: William S
authors.initials: WS
authors.lastname: Mason
authors.forename: Chunxiao
authors.initials: C
authors.lastname: Xu
authors.forename: Huey Chi
authors.initials: HC
authors.lastname: Low
authors.forename: Jeffry
authors.initials: J
authors.lastname: Saputelli
authors.forename: Carol E
authors.initials: CE
authors.lastname: Aldrich
authors.forename: Catherine
authors.initials: C
authors.lastname: Scougall
authors.forename: Arend
authors.initials: A
authors.lastname: Grosse
authors.forename: Richard
authors.initials: R
authors.lastname: Colonno
authors.forename: Sam
authors.initials: S
authors.lastname: Litwin
authors.forename: Allison R
authors.initials: AR
authors.lastname: Jilbert
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000032:analysis; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy / Q000473:pathology* / Q000821:virology*; D017919:Hepatitis B Virus, Woodchuck / Q000187:drug effects*; D022781:Hepatocytes / Q000737:chemistry / Q000821:virology*; D008115:Liver Regeneration; D008392:Marmota; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; C413685:entecavir; D006147:Guanine